Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7293583 + Tocilizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7293583 | RO-7293583|RO 7293583 | CD3 Antibody 99 | RO7293583 binds to both PRSS1 (TRP1) and CD3, potentially leads to the activation of CD3-expressing cytotoxic T lymphocytes (CTLs) and CTL-mediated killing of TYRP1-expressing tumor cells (NCI Drug Dictionary). | |
Tocilizumab | Actemra | Atlizumab | Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |